Welcome to our dedicated page for Crinetics Pharmaceuticals news (Ticker: CRNX), a resource for investors and traders seeking the latest updates and insights on Crinetics Pharmaceuticals stock.
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) generates frequent news flow around its efforts to develop and commercialize therapies for endocrine diseases and endocrine-related tumors. Company announcements highlight progress across its GPCR-targeted small-molecule portfolio, including regulatory milestones, clinical trial updates, capital markets activity, and corporate developments.
News coverage often focuses on PALSONIFY™ (paltusotine), Crinetics’ once-daily, oral somatostatin receptor type 2 agonist. Updates have included U.S. FDA approval for adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option, early launch metrics, and the design and enrollment status of the pivotal Phase 3 CAREFNDR trial in carcinoid syndrome associated with neuroendocrine tumors.
Investors and observers can also follow regular announcements on atumelnant, the company’s investigational ACTH receptor antagonist in late-stage development for classic congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing’s syndrome. Press releases describe Phase 2 results, the CALM-CAH Phase 3 trial design, biomarker changes such as reductions in androstenedione, and safety observations from both core studies and open-label extensions.
Additional news items cover the advancement of CRN09682, a nonpeptide drug conjugate targeting SST2-expressing tumors, including first-patient dosing in the Phase 1/2 BRAVESST2 trial and details of the trial’s dose-escalation and expansion phases. Crinetics also reports on preclinical programs like CRN12755 and CRN10329 through R&D Day presentations and conference abstracts.
Beyond R&D, Crinetics issues releases on public offerings of common stock, inducement equity grants under its 2021 Employment Inducement Incentive Award Plan, participation in major healthcare conferences, and executive transitions disclosed via Form 8-K. For users tracking CRNX, this news page provides a centralized view of the company’s clinical, regulatory, financial, and corporate announcements over time.
Crinetics Pharmaceuticals (Nasdaq: CRNX) announced that the FDA has granted Orphan Drug Designation for paltusotine to treat acromegaly, a rare endocrine disease. This designation incentivizes development, potentially exempting the company from user fees and providing seven years of market exclusivity upon approval. The designation highlights the promising Phase 2 clinical trial results for paltusotine. Crinetics plans to report topline results for the ACROBAT trials later this year and initiate a Phase 3 trial in 2021.
Crinetics Pharmaceuticals (Nasdaq: CRNX) announced that 28 of 47 patients have completed the ACROBAT Edge Phase 2 trial, evaluating the effects of oral paltusotine on IGF-1 levels in acromegaly patients switched from injectable treatments. Topline results from the Edge and Evolve trials, with 47 and 13 patients respectively, are expected in Q4 2020. Management is planning to initiate Phase 3 clinical development for paltusotine in early 2021 based on these results and regulatory feedback.
Crinetics Pharmaceuticals (Nasdaq: CRNX) announced the appointment of Adriana Cabré as Vice President of Human Resources, effective immediately. Cabré brings over 25 years of HR experience, previously serving as President of ACC People Strategies and Chief People Officer at National University. This leadership change aims to enhance Crinetics' culture as it expands its operations in the rare endocrine disease sector. The company's lead candidate, paltusotine, is undergoing Phase 2 trials for acromegaly, with plans for further trials in 2021.
Crinetics Pharmaceuticals (Nasdaq: CRNX) reported positive interim results from its ACROBAT Edge Phase 2 trial of oral paltusotine for acromegaly treatment. Patients switching to paltusotine maintained IGF-1 levels previously achieved with injectable therapies. A public offering raised net proceeds of $107.9 million, strengthening the company's financial position. However, R&D expenses increased to $13.9 million, leading to a net loss of $17.4 million for Q1 2020. The company anticipates advancing paltusotine into Phase 3 trials in 2021 and has ongoing programs targeting neuroendocrine tumors.